Journal profile · ONCOLOGY
Advances in Cancer Biology-Metastasis
ISSN 2667-3940 · Elsevier
Advances in Cancer Biology-Metastasis: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 4.2 (journal website); fully open access; APC about USD 3,080; review about 89 days (submission to acceptance, publisher); 35 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Advances in Cancer Biology-Metastasis is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are MicroRNA in disease regulation, Cancer-related molecular mechanisms research and Cancer Cells and Metastasis, together about 35% of its articles. Its main subfields are Cancer Research and Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Despite the progress in cancer diagnostic and treatment, the problem of cancer metastasis is still unsolved. Approximately 90% of cancer patients die due to the metastatic disease progression. It is assumed that elucidation of the molecular mechanisms associated with cancer cell spread to the distant organs and tissues could help in the improvement of therapy results and clinical outcome in cancer patients.The journal devotes itself to the publication of basic and translational research. It accepts reviews, research articles, mini-reviews and technical (methodology) papers. More clinically-oriented papers may also be accepted if they discuss therapeutic options dependent on specific molecular features of the primary and secondary (metastatic) tumors.Manuscripts addressing the following problems are especially welcome:Molecular mechanisms underlying metastatic spread;Molecular properties of carcinoma cells associated with their metastatic capacities;Molecular mechanisms of organ-specific metastasis;Role of microenvironment (tumor stroma and immune system) in metastatic progression;Site-specific metastasis;Tumor metabolism and metastatic spread;Cancer metastasis and dormancy;Role of cancer stem cells in the metastasis development;Circulating tumor cells;Exosomes and microvesicles in disease progression;Therapy-induced metastasis;Animal models to study the mechanisms of metastatic spread;Preclinical findings that could be useful in the clinical practice to combat metastatic disease;Diagnostic tools for metastasis detection;Translational research on metastatic disease;Therapeutic approaches to combat metastatic progression.Should you have a proposal or an idea for a thematic issue, please complete the thematic issue proposal form and send it to the Editorial Office (advancesincancerbiology@elsevier.com).
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Ira-Ida SkvortsovaPublisher website
Editorial board by country: none in mainland China; most named Italy 7, United States 6, Austria 5, United Kingdom 2, India 2 (30 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology12.7%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology12.3%
- Cancer Cells and MetastasisMedicine10%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology5.4%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology5.4%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology5.4%
- Extracellular vesicles in diseaseBiochemistry, Genetics and Molecular Biology4.6%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 4.2Publisher website ·
- CiteScore 2026-06
- 8.1LetPub ·
- CiteScore (publisher)
- 8.1Publisher website ·
- SJR 2026-06
- 0.86LetPub ·
- SNIP 2026-06
- 0.82LetPub ·
- h-index
- 21OpenAlex ·
- i10-index
- 45OpenAlex ·
- 2-year mean citedness
- 2.47OpenAlex ·
- Self-citation rate
- 2.4%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 29LetPub ·
Articles by year OpenAlex count · 204 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 46 | 46 | 20 |
| 2025 | 35 | 35 | 34 |
| 2024 | 15 | 15 | 183 |
| 2023 | 29 | 29 | 308 |
| 2022 | 56 | 56 | 819 |
| 2021 | 23 | 23 | 216 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
89 dayssubmission to acceptance · community reports about 10 weeks
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Average review time (community reports)
- about 10 weeksLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 41 daysPublisher website ·
- Submission to acceptance
- 89 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,080 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,650 / EUR 2,480 / GBP 2,120 / JPY 328,680 | — | — | |
| LetPub | USD 2,800 | Yes | — | |
| Publisher website | USD 3,080 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
Article types accepted4
- mini-reviewsIt accepts reviews, research articles, mini-reviews and technical (methodology) papers.Length not stated
- research articlesIt accepts reviews, research articles, mini-reviews and technical (methodology) papers.Length not stated
- reviewsIt accepts reviews, research articles, mini-reviews and technical (methodology) papers.Length not stated
- technical (methodology) papersIt accepts reviews, research articles, mini-reviews and technical (methodology) papers.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Follows Elsevier's Publishing Ethics Policy Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed, does not count as prior publication Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 2667-3940
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Advances in Cancer Biology-Metastasis
What CAS zone is Advances in Cancer Biology-Metastasis in?
In the 2025 upgraded edition of the CAS Journal Ranking, Advances in Cancer Biology-Metastasis is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Advances in Cancer Biology-Metastasis?
The journal's website gives an impact factor of 4.2; this is the journal's own figure, as LetPub lists none for it; CiteScore 8.1, h-index 21.
How long does peer review take at Advances in Cancer Biology-Metastasis?
The publisher reports about 89 days (submission to acceptance); authors report an average review time of about 10 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Advances in Cancer Biology-Metastasis?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Advances in Cancer Biology-Metastasis based?
Of the 30 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (7), United States (6) and Austria (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Advances in Cancer Biology-Metastasis?
According to LetPub and DOAJ records, Advances in Cancer Biology-Metastasis is indexed in ESCI, Scopus and DOAJ.
Is Advances in Cancer Biology-Metastasis open access, and what is the APC?
Advances in Cancer Biology-Metastasis is a fully open-access journal. APC about USD 3,080.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .